Gonorrhea

AHF Launches New Campaigns “Hook Up With Us” Addressing 6th Straight Year of Increases in STDs and “AHF Is Resilience”

Saturday, June 19, 2021 - 11:00am
Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20210619005059/en/
    In 2019, more than 2.5 million cases of chlamydia, gonorrhea, and syphilis were reported, and were the most common STDs found.
  • Undoubtedly, this causes grave concern as STDs have the potential to lead to serious health consequences, especially if untreated.
  • Past AHF billboard campaigns addressing STDs include Gonorrhea Alert , launched in June of 2018 which was a nationwide effort to educate the public about a drug-resistant strain of the STD.
  • To learn more about AHF, please visit our website: www.aidshealth.org , find us on Facebook: www.facebook.com/aidshealth and follow us on Twitter: @aidshealthcare and Instagram: @aidshealthcare .

New Data on EVO100 for the Prevention of Chlamydia and Gonorrhea in Women to be Presented at ISPOR 2021

Monday, May 17, 2021 - 1:00pm

All participants indicated that this information was important to know for women considering a microbicidal vaginal gel like EVO100.\nAbstracts have been published in the May 2021 issue of Value in Health1, the international journal of ISPOR.

Key Points: 
  • All participants indicated that this information was important to know for women considering a microbicidal vaginal gel like EVO100.\nAbstracts have been published in the May 2021 issue of Value in Health1, the international journal of ISPOR.
  • The poster is available to registered Virtual ISPOR 2021 attendees at https://virtualispor2021.secure-platform.com/a/organizations/main/home and will be available following the conference at https://www.evofem.com/posters-and-publications/ .\nEnrollment is underway in EVOGUARD, the pivotal Phase 3 clinical trial of EVO100 for prevention of chlamydia and gonorrhea in women.
  • All 90 planned study centers have been identified and more than 80 sites have been activated.
  • The Company expects to complete enrollment by year-end 2021 and to report top-line data in mid-2022.

Evofem Biosciences Receives Fast Track Designation for EVO100 for Prevention of Gonorrhea in Women

Wednesday, May 12, 2021 - 2:00pm

b'SAN DIEGO, May 12, 2021 /PRNewswire/ --Evofem Biosciences, Inc., (NASDAQ: EVFM) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for EVO100 for the prevention of urogenital gonorrhea in women.

Key Points: 
  • b'SAN DIEGO, May 12, 2021 /PRNewswire/ --Evofem Biosciences, Inc., (NASDAQ: EVFM) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for EVO100 for the prevention of urogenital gonorrhea in women.
  • "\nEVO100 previously received Fast Track designation from the FDA for the prevention of chlamydia in women and was also designated as a Qualified Infectious Disease Product (QIDP) by the FDA for the prevention of gonorrhea in women.
  • A drug that receives QIDP designationmay qualify for an additional five years of marketing exclusivity.\nEvofem\'s pivotal Phase 3 clinical trial of EVO100 for prevention of chlamydia and gonorrhea in women, EVOGUARD , is currently enrolling 1,730 women in U.S. study sites.
  • This double-blinded, placebo-controlled study of EVO100 met its primary and secondary efficacy endpoints, with statistically significant reductions in the risk of chlamydia and gonorrhea infections.

SpeeDx Receives CARB-X Funding to Develop Rapid Point-of-Care Diagnostic

Monday, May 10, 2021 - 9:00pm

SpeeDx represents the first Australian-based diagnostics company to receive CARB-X funding and a further $1.9 million will be available once the project reaches defined milestones.

Key Points: 
  • SpeeDx represents the first Australian-based diagnostics company to receive CARB-X funding and a further $1.9 million will be available once the project reaches defined milestones.
  • Funds will be used to develop a rapid test for the combined detection of Chlamydia trachomatis and Neisseria gonorrhoeae, while identifying antimicrobial resistance (AMR) of gonorrhea infections towards common antibiotic treatments.
  • SpeeDx will utilize their newly patented InSignia\xe2\x84\xa2 technology to both assess the presence of active bacterial infection and AMR status.
  • SpeeDx specializes in molecular diagnostic solutions that go beyond simple detection to offer comprehensive information for improved patient management.

Entasis Therapeutics Completes Initial Closing of $20M Private Placement with Innoviva

Monday, May 3, 2021 - 9:05pm

Entasis\xe2\x80\x99 pipeline includes sulbactam-durlobactam (SUL-DUR) for carbapenem-resistant Acinetobacter baumannii infections, and zoliflodacin for uncomplicated gonorrhea, including infections caused by drug-resistant strains of Neisseria gonorrhoeae.

Key Points: 
  • Entasis\xe2\x80\x99 pipeline includes sulbactam-durlobactam (SUL-DUR) for carbapenem-resistant Acinetobacter baumannii infections, and zoliflodacin for uncomplicated gonorrhea, including infections caused by drug-resistant strains of Neisseria gonorrhoeae.
  • At the initial closing, which occurred on May 3, 2021, Innoviva purchased approximately 3.7 million shares of common stock and warrants to purchase approximately 3.7 million shares of common stock for an aggregate purchase price of approximately $7.5 million.
  • For more information, visit www.entasistx.com .\nThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.
  • These forward-looking statements are based on Entasis\xe2\x80\x99 expectations and assumptions as of the date of this press release.

Under 30 and sexually active? It's a good idea to get tested for chlamydia and gonorrhea

Monday, April 19, 2021 - 1:05pm

Without treatment, these infections can lead to pelvic inflammatory disease, pain and possibly infertility.\n"If people are under 30 and sexually active, it\'s a good idea to get tested," says Dr. Ainsley Moore, a family physician and associate clinical professor, Department of Family Medicine, McMaster University, and chair of the Task Force chlamydia and gonorrhea working group.

Key Points: 
  • Without treatment, these infections can lead to pelvic inflammatory disease, pain and possibly infertility.\n"If people are under 30 and sexually active, it\'s a good idea to get tested," says Dr. Ainsley Moore, a family physician and associate clinical professor, Department of Family Medicine, McMaster University, and chair of the Task Force chlamydia and gonorrhea working group.
  • "Many people are asymptomatic and may not seek treatment so we\'re recommending opportunistic testing, that is, at any health care visit.
  • "\nThe guideline recommends that health care providers in Canada offer routine screening (testing) for chlamydia and gonorrhea to all sexually active patients under age 30 not known to belong to a high-risk group.
  • The task force\'s mandate is to develop and disseminate evidence-based clinical practice guidelines for primary and preventive care.\n'

Evofem Biosciences Announces Publication in American Journal of Obstetrics and Gynecology of AMPREVENCE Study of EVO100 for Chlamydia and Gonorrhea Prevention

Tuesday, March 16, 2021 - 12:00pm

Evofem's dedication to bringing EVO100 to market as quickly and safely as possible underscores our commitment to serving women."

Key Points: 
  • Evofem's dedication to bringing EVO100 to market as quickly and safely as possible underscores our commitment to serving women."
  • Building on the AMPREVENCE results, Evofem is currently enrolling EVOGUARD , its pivotal Phase 3 clinical trial of EVO100 for prevention of chlamydia and gonorrhea in women.
  • The in-press accepted manuscript, entitledEVO100 Prevents Chlamydia and Gonorrhea in Women at High-Risk for Infection, is available online at https://www.sciencedirect.com/science/article/abs/pii/S0002937821001563 .
  • AMPREVENCE was conducted over approximately 16 weeks in women age 18 to 45 years who were at risk of urogenital chlamydia and gonorrhea infection.

Testing.com Announces Best Free STD Testing Organizations in Columbus, OH

Friday, March 12, 2021 - 5:00am

SEATTLE, March 12, 2021 /PRNewswire-PRWeb/ -- Testing.com , a trusted informational guide for medical lab testing and at-home screening, has published a report on the increasing STD cases and resources for addressing this issue in Columbus, including top local organizations with free or low-cost health screening options for residents.

Key Points: 
  • SEATTLE, March 12, 2021 /PRNewswire-PRWeb/ -- Testing.com , a trusted informational guide for medical lab testing and at-home screening, has published a report on the increasing STD cases and resources for addressing this issue in Columbus, including top local organizations with free or low-cost health screening options for residents.
  • According to the Chlamydia Five Year Report published by the Ohio Department of Health, the number of reported chlamydia cases in Franklin County increased from 8,088 to 10,179 between 2014 and 2018 while Ohio's Gonorrhea Five Year Report shows a drastic increase in the number of reported cases of gonorrhea statewide between 2014 and 2018.
  • The Total Syphilis Five Year Report states that while the number of reported syphilis cases in Columbus declined by 25% between 2016 and 2017, the city still leads the state in the number of reported cases.
  • The report features the following organizations:

Testing.com Announces Best Free STD Testing Organizations in Des Moines, Iowa

Friday, March 12, 2021 - 5:00am

SEATTLE, March 12, 2021 /PRNewswire-PRWeb/ -- Testing.com , a trusted informational guide for medical lab testing and at-home screening, has published a report on the increasing STD cases and resources for addressing this issue in Des Moines, including top local organizations with free or low-cost health screening options for residents.

Key Points: 
  • SEATTLE, March 12, 2021 /PRNewswire-PRWeb/ -- Testing.com , a trusted informational guide for medical lab testing and at-home screening, has published a report on the increasing STD cases and resources for addressing this issue in Des Moines, including top local organizations with free or low-cost health screening options for residents.
  • According to the report, despite Iowa being a rural state, incidences of STDs are following the national trend.
  • Chlamydia infections have increased for the last five years in Polk County, according to the Polk County Health Department's Chlamydia 2015-2019 Polk County Report while The Polk County Health Department's Gonorrhea 2015-2019 Polk County Report documented a startling 121.8% increase in gonorrhea cases.
  • After an encouraging drop of 32.4% in total syphilis cases in 2018, Polk County cases took a dramatic jump in 2019.

Testing.com Announces Best Free STD Testing Organizations in College Station, TX

Friday, March 12, 2021 - 5:00am

SEATTLE, March 12, 2021 /PRNewswire-PRWeb/ -- Testing.com , a trusted informational guide for medical lab testing and at-home screening, has published a report on the increasing STD cases and resources for addressing this issue in College Station, including top local organizations with free or low-cost health screening options for residents.

Key Points: 
  • SEATTLE, March 12, 2021 /PRNewswire-PRWeb/ -- Testing.com , a trusted informational guide for medical lab testing and at-home screening, has published a report on the increasing STD cases and resources for addressing this issue in College Station, including top local organizations with free or low-cost health screening options for residents.
  • According to the report, that three most common STDs in College Station are chlamydia, gonorrhea, and syphilis.
  • Nine of the cases in the county were primary and secondary syphilis, and two of the P&S diagnoses were in College Station.
  • The report features the following organizations: